Boston Scientific Corporation BSX
44.70 USD +0.68 (+1.54%)
At closeNov 11, 2026, 5:42 AM EST
44.22 -0.48 -1.07%
Pre-market · Nov 11, 5:42 AM ET
43.40 Day range 44.78
39.57 52-week range 105.65
- YTD
- -53.12%
- 1 year
- -55.70%
News
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Boston Scientific Corporation - BSX NEW YORK, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX). Such…
zacks.com Wall Street Analysts Look Bullish on Boston Scientific (BSX): Should You Buy? Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm…
defenseworld.net Boston Scientific Corporation $BSX Stock Bought by Ethic Inc. Ethic Inc. boosted its position in Boston Scientific Corporation (NYSE: BSX) by 11.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange…
businesswire.com BOSTON SCIENTIFIC CORPORATION INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Boston Scientific Corporation's Directors and Officers for Breach of Fiduciary Duties – BSX NEW YORK--(BUSINESS WIRE)---- $BSX #NYSE--Scott+Scott Attorneys at Law LLP has launched an urgent investigation into whether certain officers and directors of Boston Scientific Corporation (NYSE:…
zacks.com Here is What to Know Beyond Why Boston Scientific Corporation (BSX) is a Trending Stock Boston Scientific (BSX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
benzinga.com Here’s How Much You Would Have Made Owning Boston Scientific Stock In The Last 15 Years Boston Scientific (NYSE:BSX) has outperformed the market over the past 15 years by 1.84% on an annualized basis producing an average annual return of 14.73%. Currently, Boston Scientific has a market…
zacks.com BSX Q3 Results Reset Growth Expectations as 2027 Outlook Stays Weak Boston Scientific's cyber disruption cuts Q3 growth and earnings, forcing lower 2026 guidance as management sees 2027 as the cycle's trough.
benzinga.com TD Cowen Downgrades Boston Scientific to Hold, Lowers Price Target to $46 TD Cowen analyst Joshua Jennings downgrades Boston Scientific (NYSE:BSX) from Buy to Hold and lowers the price target from $56 to $46.
benzinga.com Barclays Maintains Equal-Weight on Boston Scientific, Lowers Price Target to $45 Barclays analyst Christopher Pasquale maintains Boston Scientific (NYSE:BSX) with a Equal-Weight and lowers the price target from $48 to $45.- benzinga.com Jefferies Downgrades Boston Scientific to Hold, Lowers Price Target to $46 Jefferies analyst Matthew Taylor downgrades Boston Scientific (NYSE:BSX) from Buy to Hold and lowers the price target from $60 to $46.
- benzinga.com Canaccord Genuity Maintains Buy on Boston Scientific, Lowers Price Target to $48 Canaccord Genuity analyst William Plovanic maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $66 to $48.
benzinga.com RBC Capital Maintains Outperform on Boston Scientific, Lowers Price Target to $52 RBC Capital analyst Kendall Au maintains Boston Scientific (NYSE:BSX) with a Outperform and lowers the price target from $70 to $52.- benzinga.com Citigroup Maintains Neutral on Boston Scientific, Lowers Price Target to $44 Citigroup analyst Joanne Wuensch maintains Boston Scientific (NYSE:BSX) with a Neutral and lowers the price target from $48 to $44.
- benzinga.com Leerink Partners Maintains Outperform on Boston Scientific, Lowers Price Target to $50 Leerink Partners analyst Mike Kratky maintains Boston Scientific (NYSE:BSX) with a Outperform and lowers the price target from $55 to $50.
benzinga.com UBS Maintains Buy on Boston Scientific, Lowers Price Target to $57 UBS analyst Patrick Wood maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $67 to $57.
benzinga.com Wells Fargo Maintains Equal-Weight on Boston Scientific, Lowers Price Target to $45 Wells Fargo analyst Larry Biegelsen maintains Boston Scientific (NYSE:BSX) with a Equal-Weight and lowers the price target from $48 to $45.
benzinga.com These Analysts Revise Their Forecasts On Boston Scientific After Q3 Results Boston Scientific beat Q3 estimates but cut FY26 guidance; Q4 forecasts missed expectations. Analysts adjusted price targets.
benzinga.com Baird Maintains Outperform on Boston Scientific, Raises Price Target to $51 Baird analyst David Rescott maintains Boston Scientific (NYSE:BSX) with a Outperform and raises the price target from $50 to $51.- benzinga.com BTIG Maintains Buy on Boston Scientific, Lowers Price Target to $49 BTIG analyst Marie Thibault maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $56 to $49.
benzinga.com Needham Maintains Buy on Boston Scientific, Lowers Price Target to $48 Needham analyst Mike Matson maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $57 to $48.
benzinga.com Boston Scientific Overshadowed by Hackers, Headwinds, and Lower Guidance Boston Scientific slips after a cyber fallout offsets a Q3 consensus beat. Management targets a 2027 cycle trough and 2030 expansion.
benzinga.com Boston Scientific Q3 2026 Earnings Call Transcript Boston Scientific (NYSE:BSX) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This content is powered by…- benzinga.com Boston Scientific Lowers FY2026 Adj EPS Guidance from $3.28-$3.32 to $3.16-$3.18 vs $3.23 Est; Lowers FY2026 Sales Guidance from $21.178B-$21.379B to $20.927B vs $21.143B Est Boston Scientific (NYSE:BSX) lowers FY2026 Adj EPS guidance from $3.28-$3.32 to $3.16-$3.18 vs $3.23 analyst estimate. Lowers FY2026 sales outlook from $21.178 billion-$21.379 billion to $20.927…
benzinga.com Boston Scientific Sees Q4 Adj EPS $0.77-$0.79 vs $0.84 Est; Sees Sales $5.127B-$5.233B vs $5.404B Est Boston Scientific (NYSE:BSX) is looking for Q4 Adj EPS of $0.77-$0.79 vs $0.84 analyst estimate. sees sales of $5.127 billion-$5.233 billion vs $5.404 billion analyst estimate.- benzinga.com Boston Scientific Q3 Adj. EPS $0.73 Beats $0.72 Estimate, Sales $5.138B Beat $5.046B Estimate Boston Scientific (NYSE:BSX) reported quarterly earnings of $0.73 per share which beat the analyst consensus estimate of $0.72 by 1.39 percent. This is a 2.67 percent decrease over earnings of $0.75…
benzinga.com Microsoft, Alphabet On Deck Wednesday As AI Spending, Cloud Growth Face Test Microsoft and Alphabet headline Wednesday’s reports, with investors weighing whether AI infrastructure spending is translating into durable cloud and advertising growth. GE Vernova, Amphenol, Banco…- benzinga.com Stifel Maintains Buy on Boston Scientific, Lowers Price Target to $55 Stifel analyst Rick Wise maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $60 to $55.
- benzinga.com Truist Securities Maintains Buy on Boston Scientific, Lowers Price Target to $51 Truist Securities analyst Richard Newitter maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $57 to $51.
- tradingkey.com HIMS News Get the latest Hims & Hers Health Inc (HIMS) stock news, including earnings updates, analyst ratings, company announcements and market-moving events.
finance.yahoo.com Wall Street Analysts Look Bullish on Boston Scientific (BSX): Should You Buy? Boston Scientific (BSX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast ...
royalgazette.com Allshores and Butterfield shares trade on BSX Shares of two companies traded on the Bermuda Stock Exchange, as The Royal Gazette/BSX Index closed unchanged on 3,463.38 ...
msn.com IELTS co-owner IDP jumps 16% after Blackstone sweetens bid again By Kumar Tanishk and Jasmeen Ara Islam Shaikh Nov 11 (Reuters) - Shares of Australia's IDP Education rose more than 16% on ...
- business-standard.com IIFL Finance-Blackstone deal: Stock gains 4%; brokerages decode impact US-based Blackstone, the world's largest alternative asset manager, will invest ₹5,000 crore (about $535 million) for a nearly 16 per cent stake in IIFL Finance ...
telegraphindia.com Blackstone to acquire 16% stake in IIFL Finance for Rs 5,000 crore in major deal Blackstone, the world’s largest alternative asset manager, will acquire an approximately 16 per cent stake in IIFL Finance ...
- msn.com Blackstone to buy 16% in IIFL Finance for Rs 5,000 crore: What's the deal all about Global investment titan Blackstone is poised to acquire a 16% stake in IIFL Finance for a whopping Rs 5,000 crore. This strategic investment is part of a broader Rs 6,414 crore fundraising initiative…
- sharewise.com EQS-News: Gabler Group AG Invites to Earnings Call on Unaudited Q3 2026 Results Miscellaneous Gabler Group AG Invites to Earnings Call on Unaudited Q3 2026 Results 10.11.2026 / 12:45 CET/CEST The issuer is solely responsible for ...
- zeebiz.com IIFL Finance Share Price: NBFC stock jumps after Rs 6,414 crore Blackstone deal; MOFSL, HSBC see up to 33% upside IIFL Finance shares rose over 2 per cent in early trade on Wednesday after the company announced a Rs 6,414 crore primary equity investment led by Blackstone.
sharewise.com EQS-News: Telefónica Deutschland and freenet lay the foundation for another ten years of partnership Agreement Telefónica Deutschland and freenet lay the foundation for another ten years of partnership 10.11.2026 / 17:45 ...
- financialcontent.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Boston Scientific Corporation - BSX NEW YORK, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX). Such ...